Trial · NCT05282121
Adverse events164
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 164
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Pericardial effusion | Cardiac disorders | Patients With HBV - Avenciguat | 1 | 14 | |
| other | Pericardial effusion | Cardiac disorders | Patients With HCV - Avenciguat | 0 | 13 | |
| other | Pericardial effusion | Cardiac disorders | Patients With NASH With or Without T2DM - Avenciguat | 0 | 38 | |
| other | Pericardial effusion | Cardiac disorders | Patients With NASH With T2DM - Avenciguat + Empagliflozin | 0 | 25 | |
| other | Dry eye | Eye disorders | Patients With HBV - Avenciguat | 1 | 14 | |
| other | Dry eye | Eye disorders | Patients With HCV - Avenciguat | 0 | 13 | |
| other | Dry eye | Eye disorders | Patients With NASH With or Without T2DM - Avenciguat | 0 | 38 | |
| other | Dry eye | Eye disorders | Patients With NASH With T2DM - Avenciguat + Empagliflozin | 0 | 25 | |
| other | Abdominal pain | Gastrointestinal disorders | Patients With HBV - Avenciguat | 1 | 14 | |
| other | Abdominal pain | Gastrointestinal disorders | Patients With HCV - Avenciguat | 0 | 13 | |
| other | Abdominal pain | Gastrointestinal disorders | Patients With NASH With or Without T2DM - Avenciguat | 3 | 38 | |
| other | Abdominal pain | Gastrointestinal disorders | Patients With NASH With T2DM - Avenciguat + Empagliflozin | 1 | 25 | |
| other | Abdominal pain upper | Gastrointestinal disorders | Patients With HBV - Avenciguat | 1 | 14 | |
| other | Abdominal pain upper | Gastrointestinal disorders | Patients With HCV - Avenciguat | 0 | 13 | |
| other | Abdominal pain upper | Gastrointestinal disorders | Patients With NASH With or Without T2DM - Avenciguat | 0 | 38 | |
| other | Abdominal pain upper | Gastrointestinal disorders | Patients With NASH With T2DM - Avenciguat + Empagliflozin | 1 | 25 | |
| other | Ascites | Gastrointestinal disorders | Patients With HBV - Avenciguat | 1 | 14 | |
| other | Ascites | Gastrointestinal disorders | Patients With HCV - Avenciguat | 0 | 13 | |
| other | Ascites | Gastrointestinal disorders | Patients With NASH With or Without T2DM - Avenciguat | 3 | 38 | |
| other | Ascites | Gastrointestinal disorders | Patients With NASH With T2DM - Avenciguat + Empagliflozin | 1 | 25 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05282121/events